ValuEngine upgraded shares of Athersys, Inc. (NASDAQ:ATHX) from a sell rating to a hold rating in a research note released on Friday morning.
ATHX has been the topic of several other research reports. Maxim Group reiterated a buy rating and issued a $12.00 price objective on shares of Athersys in a report on Friday, September 1st. Zacks Investment Research upgraded Athersys from a hold rating to a buy rating and set a $2.00 price objective on the stock in a report on Tuesday, August 29th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Athersys currently has a consensus rating of Buy and a consensus target price of $7.17.
Athersys (NASDAQ:ATHX) opened at 2.38 on Friday. Athersys has a 52-week low of $1.02 and a 52-week high of $2.44. The stock’s 50 day moving average price is $1.74 and its 200-day moving average price is $1.53. The company’s market cap is $271.11 million.
Athersys (NASDAQ:ATHX) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The firm had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.96 million. Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.08) EPS. On average, equities analysts predict that Athersys will post ($0.24) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/19/athersys-inc-athx-upgraded-at-valuengine.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATHX. Teachers Advisors LLC grew its stake in Athersys by 21.9% during the 4th quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 28,178 shares in the last quarter. Wells Fargo & Company MN grew its stake in Athersys by 4.8% during the 1st quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,800 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Athersys by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 265,165 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 26,526 shares in the last quarter. TFS Capital LLC acquired a new position in Athersys during the 1st quarter worth $149,000. Finally, Vanguard Group Inc. grew its stake in Athersys by 19.5% during the 1st quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock worth $6,668,000 after purchasing an additional 637,322 shares in the last quarter. 19.08% of the stock is owned by hedge funds and other institutional investors.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.